HBsAg kinetics after 7 years of therapy with tenofovir disoproxil fumarate in a cohort of naïve patients affected by chronic hepatitis B with different genotypes
作者机构：Department of Translational MedicineUniversity of Eastern Piedmont28100 NovaraItaly Department of Medical SciencesInfectious DiseasesUniversity of Turin10138 TurinItaly
出 版 物：《Infectious Medicine》 (感染医学（英文）)
年 卷 期：2024年第3卷第1期
页 面：75-78页
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
主 题：Hepatitis B Tenofovir disoproxil fumarate HBsAg decline Serological response Entecavir
摘 要：Background:The role of different genotypes in nucleos(t)ide analogs(NAs)treatment is still *** studies conducted on special populations evidenced that the E genotype had the lower virological and serological *** descriptive study aims to recognize the hepatitis B“santigen(HBsAg)decline during tenofovir disoproxil fumarate(TDF)treatment in a cohort of patient affected by chronic hepatitis B(CHB).Methods:We retrospectively included all patients with CHB treated with TDF between April 2007 and March 2012 with a duration of treatment of 7 *** of HBsAg was determined as serological response in this *** include 110 subjects;virological response was observed in all subjects with genotypes A,B,and D;in 17 patients with C genotype(94.4%)and 24 with E genotype(96%).HBeAg loss was observed in 2 patients with genotype A(50%),3 with B(100%),0 with C(0%),1 with D(20%),and 1 with E genotype(25%).Results:In multivariate analysis we observed as predictive factors of HBsAg decline the baseline level of HBsAg(OR=1.467;95%CI:1.221–5.113;p=0.017)and viral genotypes(OR=11.218;95%CI:5.441–41.138;p0.001).Conclusion:This study confirmed higher HBsAg decline after 7 years of treatment in A and B genotypes,and lower in C,E,and D ***,no evidence is enough to choose a single NAs,but in special populations,as well as in genotype E,the use of TDF should be preferred to entecavir.
维普期刊数据库